Meta-analysis: Duration of First-Line Proton-Pump InhibitorBased Triple Therapy for Helicobacter pylori Eradication

@article{Fuccio2007MetaanalysisDO,
  title={Meta-analysis: Duration of First-Line Proton-Pump InhibitorBased Triple Therapy for Helicobacter pylori Eradication},
  author={L. Fuccio and M. E. Minardi and R. M. Zagari and D. Grilli and N. Magrini and F. Bazzoli},
  journal={Annals of Internal Medicine},
  year={2007},
  volume={147},
  pages={553-562}
}
  • L. Fuccio, M. E. Minardi, +3 authors F. Bazzoli
  • Published 2007
  • Medicine
  • Annals of Internal Medicine
  • Helicobacter pylori infection causes chronic gastritis and is associated with increased risk for major upper gastrointestinal diseases, such as peptic ulcer disease, gastric adenocarcinoma, and mucosa-associated lymphoid tissue lymphoma (1). Proton-pump inhibitor (PPI)based triple therapy, composed of a PPI, clarithromycin, and either amoxicillin or metronidazole, is a widely recommended eradication therapy. However, there is still no consensus on the optimal duration of treatment (7, 10, or 14… CONTINUE READING

    Citations

    Publications citing this paper.
    SHOWING 1-10 OF 234 CITATIONS, ESTIMATED 41% COVERAGE

    Prolonged treatment duration is required for successful Helicobacter pylori eradication with proton pump inhibitor triple therapy in Canada.

    VIEW 1 EXCERPT
    CITES RESULTS

    Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori

    VIEW 1 EXCERPT
    CITES BACKGROUND

    Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection.

    FILTER CITATIONS BY YEAR

    2007
    2020

    CITATION STATISTICS

    • 2 Highly Influenced Citations

    • Averaged 6 Citations per year from 2018 through 2020

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 59 REFERENCES

    Seven-day therapy for Helicobacter pylori in the United States.

    VIEW 7 EXCERPTS
    HIGHLY INFLUENTIAL

    The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.

    • V. de Francesco, A. Zullo, +9 authors E. Ierardi
    • Medicine
    • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
    • 2004
    VIEW 3 EXCERPTS